SCHEMBL4548658

SCHEMBL4548658

CNc1nccc(Oc2ccc3c(C(=O)Nc4cc(C(F)(F)F)ccc4N(C)CCCN(C)C)cccc3c2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.63
TEK Q02763 6/20 0.63
RET P07949 4/20 0.59
PDGFRB P09619 3/20 0.59
MAPK14 Q16539 2/20 0.59
LCK P06239 2/20 0.59
AURKA O14965 1/20 0.59
ABL1 P00519 1/20 0.59
EGFR P00533 1/20 0.59
NTRK1 P04629 1/20 0.59
INSR P06213 1/20 0.59
FES P07332 1/20 0.59
CSF1R P07333 1/20 0.59
LYN P07948 1/20 0.59
IGF1R P08069 1/20 0.59
MET P08581 1/20 0.59
FGR P09769 1/20 0.59
SRC P12931 1/20 0.59
AKT1 P31749 1/20 0.59
CSK P41240 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548657 0.91 KDR (0.65) KDRTEKRETPDGFRBMAPK14
SCHEMBL4548732 0.86 KDR (0.55) KDRTEKRETPDGFRBMAPK14
SCHEMBL10280658 0.85 KDR (0.65) KDRRETPDGFRBMAPK14FLT1
SCHEMBL2748320 0.83 KDR (0.68) KDRTEKLCKAURKAMET
SCHEMBL4548662 0.82 KDR (0.52) KDRTEKRETPDGFRBMAPK14
SCHEMBL4548773 0.81 KDR (0.79) KDRRETPDGFRBMAPK14FLT1
SCHEMBL2747450 0.80 KDR (0.78) KDRRETPDGFRBMAPK14FLT1
SCHEMBL4548656 0.79 TEK (0.62) KDRTEKRETPDGFRBMAPK14
SCHEMBL4548660 0.78 KDR (0.52) KDRTEKRETPDGFRBMAPK14
SCHEMBL1265824 0.78 TEK (1.00) KDRTEKRETPDGFRBMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885TEK 184/4885RET 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.